191 related articles for article (PubMed ID: 36637997)
1. Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis.
Wang YA; Neff R; Song WM; Zhou X; Vatansever S; Walsh MJ; Chen SH; Zhang B
FEBS Open Bio; 2023 Apr; 13(4):617-637. PubMed ID: 36637997
[TBL] [Abstract][Full Text] [Related]
2. MMDAE-HGSOC: A novel method for high-grade serous ovarian cancer molecular subtypes classification based on multi-modal deep autoencoder.
Wang HQ; Li HL; Han JL; Feng ZP; Deng HX; Han X
Comput Biol Chem; 2023 Aug; 105():107906. PubMed ID: 37336028
[TBL] [Abstract][Full Text] [Related]
3. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
4. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
[TBL] [Abstract][Full Text] [Related]
6. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
7. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
8. A novel subtype to predict prognosis and treatment response with DNA driver methylation-transcription in ovarian cancer.
Xu Z; Zhang L; Wang M; Huang Y; Zhang M; Li S; Wang L; Li K; Hou Y
Epigenomics; 2022 Sep; 14(18):1073-1088. PubMed ID: 36200265
[TBL] [Abstract][Full Text] [Related]
9. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
10. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
11. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
12. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
13. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
14. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
16. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
17. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
18. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R; Matsumura N; Michimae H; Tanabe H; Yunokawa M; Iwase H; Sasagawa M; Nakamura T; Tokuyama O; Takano M; Sugiyama T; Sawasaki T; Isonishi S; Takehara K; Nakai H; Okamoto A; Mandai M; Konishi I
Gynecol Oncol; 2019 May; 153(2):312-319. PubMed ID: 30853361
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
20. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
